Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering

APM 01.02.2025

Full Press ReleaseSEC FilingsOur APM Tweets

About Gravity Analytica

Recent News

  • 01.02.2025 - Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering
  • 12.20.2024 - Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024
  • 04.30.2024 - Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update

Recent Filings

  • 01.10.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
  • 01.07.2025 - EX-99.1 EX-99.1
  • 01.07.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]

NEW YORK,Jan. 02, 2025(GLOBE NEWSWIRE) --Aptorum Group Limited(NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today announced that it has entered into a securities purchase agreement with several institutional investors to purchase 1,535,000 Class A Ordinary Shares (the “Ordinary Shares”) in a registered direct offering. The ordinary shares are being sold at an offering price of$2.00per share.

The gross proceeds to the Company from the registered direct offering are estimated to be approximately$3.0 millionbefore deducting the placement agent’s fees and other estimated offering expenses payable by the Company. The offering is expected to close on or aboutJanuary 3, 2025, subject to the satisfaction of customary closing conditions.

Maxim Group LLCis acting as the sole placement agent in connection with the offering.

The Ordinary Shares are being offered pursuant to a shelf registration statement on Form F-3 (File No. 333-268873), which was declared effective by theU.S. Securities and Exchange Commission(the “SEC”) onJanuary 19, 2023. The offering will be made only by means of a prospectus supplement that forms a part of such registration statement.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A prospectus supplement relating to the ordinary shares will be filed by the Company with theSEC. When available, copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at theSEC'swebsite atwww.sec.govor fromMaxim Group LLC,300 Park Avenue,New York, NY10022, Attention:Syndicate Department, or via email atsyndicate@maximgrp.comor telephone at (212) 895-3500.

AboutAptorum Group Limited

Aptorum Group Limited(Nasdaq: APM) is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline ofAptorumis also enriched through the co-development of PathsDxTest, a novel molecular-based rapid pathogen identification and detection diagnostics technology, withAccelerate Technologies Pte Ltd, commercialization arm of the Singapore’sAgency for Science, Technology and Research.

Forward-Looking Statements:

This press release does not constitute an offer to sell or a solicitation of offers to buy any securities ofAptorum Group.

This press release includes statements concerningAptorum Group Limitedand its future expectations, plans and prospects that constitute “forward-looking statements” within the meaning of the US Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions.Aptorum Grouphas based these forward-looking statements largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations.

These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20-F and other filings thatAptorum Groupmay make with theSECin the future. As a result, the projections included in such forward-looking statements are subject to change and actual results may differ materially from those described herein.

Aptorum Groupassumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

This press release is provided “as is” without any representation or warranty of any kind.

Contact:

Aptorum Group LimitedInvestor Relations Departmentinvestor.relations@aptorumgroup.com+44 20 80929299

Aptorum Group Ltd

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com